Sign In
Buy AMLX
$13.20
-0.0900 (-0.677%)
At Close: Jun 03, 2026
Amylyx Pharmaceuticals's ALS dug rejected again by EU regulators
11:38am, Friday, 13'th Oct 2023
Amylyx Pharmaceuticals shares fell Friday after its ALS (amyotrophic lateral sclerosis) drug was denied marketing authorization by European Union regulators for the second time. The repeat rebuff co
Amylyx Pharmaceuticals shares fall after ALS treatment is rejected by European regulator
08:31am, Friday, 13'th Oct 2023
Amylyx Pharmaceuticals Inc. AMLX, -4.60% shares fell 7.5% premarket on Friday after the company said the European Medicines Agency had confirmed its negative opinion on Albrioza, a treatment for amyot
EU regulator declines to recommend Amylyx' ALS drug
08:28am, Friday, 13'th Oct 2023
Amylyx Pharmaceuticals said on Friday the European Union medicines regulator for the second time declined to recommend a marketing authorisation for the company's drug to treat amyotrophic lateral scl
2 Incredible Growth Stocks Near 52-Week Lows to Buy Now
09:45am, Tuesday, 10'th Oct 2023
Growth stocks have wilted under an avalanche of macro headwinds in late 2023. This broad sell-off, though, may have created some incredible bargains.
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List
11:53pm, Monday, 28'th Aug 2023
Investing in biotech stocks is challenging even when you're investing in established companies with commercially available drugs and expansive pipelines. And investing in up-and-coming biotech stocks
Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue Estimates
06:16pm, Thursday, 10'th Aug 2023
Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.93 per share a year ago.
3 Biotech Stocks to Buy Before Drug Trials End
12:56pm, Friday, 28'th Jul 2023
Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to receive FDA approval.
Why Shares of Amylyx Pharmaceuticals Were Up Monday
12:17pm, Monday, 24'th Jul 2023
Amylyx focuses on neurodegenerative diseases. After launching its first product in September, the company turned its first profitable quarter.
3 Stocks Worth a Buy for Remarkable Earnings Acceleration
08:19am, Tuesday, 18'th Jul 2023
Some of the notable companies to have witnessed solid earnings acceleration as of now are Carnival (CCL), Amylyx Pharmaceuticals (AMLX) and Alkami Technology (ALKT).
Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate
12:01pm, Monday, 26'th Jun 2023
Amylyx's (AMLX) shares plunge on getting a negative opinion from the Committee for Medicinal Products for Human Use for the marketing authorization of AMX0035, used to treat amyotrophic lateral sclero
Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics?
11:15am, Tuesday, 13'th Jun 2023
Amylyx Pharmaceuticals and Viking Therapeutics have been on fire over the past year. Even so, both companies still look incredibly undervalued relative to their long-term growth potential.
Amylyx Pharmaceuticals: Post Q1 Selloff Appears Overdone
11:48am, Wednesday, 31'st May 2023
Shares have lost a third of their value year to date. Relyvrio launch in ALS has produced promising metrics out of the gate and the company will be generating positive cash flow going forward. The con
Amylyx says European drug regulator likely to reject ALS drug
08:43am, Tuesday, 30'th May 2023
Amylyx Pharmaceuticals Inc said on Tuesday the European drug regulator was likely to reject its amyotrophic lateral sclerosis (ALS) drug, sending its shares down 8.5% in premarket trading.
Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch
07:43am, Tuesday, 16'th May 2023
The biotech sector is notoriously volatile, populated with plenty of unprofitable companies that soar on optimism about clinical trials. Those same stocks can later plummet on poor trial results, or a
Amylyx: A Biotech Underdog's Resilient Performance And Promising Market Potential
05:40am, Monday, 15'th May 2023
Amylyx Pharmaceuticals, a biotech firm focusing on neurodegenerative disorders, has seen impressive Q1 2023 financial performance despite clinical uncertainties around its flagship product, Relyvrio.
